The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
Organ Transplants triple across the country; rise from 5000 (2013) to more than 15000 in 2022
The partnership will capitalize on the combined capabilities of the two organizations
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The business and product range of Ipca and that of Unichem complements each others business and product range
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
Subscribe To Our Newsletter & Stay Updated
